What association between combined oral contraceptives such as Marvelon and breast cancer diagnosis is described in its product information?

Marvelon's product information reports a slightly increased relative risk of breast cancer diagnosis in current combined oral contraceptive users (RR 1.24), with a small absolute excess that appears to disappear by 10 years after stopping; earlier diagnosis, biological effects or both may explain the association.